COVID-19 И СОПУТСТВУЮЩАЯ ОНКОЛОГИЧЕСКАЯ ПАТОЛОГИЯ: ТЕРАПЕВТИЧЕСКИЕ ВОЗМОЖНОСТИ И СЛОЖНОСТИ
Авторы
- А. С. Патания Медицинский центр Университета Небраски
- Ф. Пратипати Национальный институт биомедицинских инноваций, здоровья и питания
- Б. А. А. Абдул Университет ПРИСТ
- С. Чава Медицинский центр Университета Небраски
- С. С. Катта Университет РЕВА, Парк знаний Рукмини Каттигенахалли
- С. К. Гупта Банарасский Индуистский университет
- П. Р. Гангула Медицинский колледж Мехарри
- М. К. Пандей Медицинская школа Купера Университета Роуэн
- Д. Л. Дерден Онкологический институт Левина; Университет Калифорнии; СигналРкс Фармасьютикалс
- С. Н. Байраредди Медицинский центр Университета Небраски
- К. Б. Чаллагундла Медицинский центр Университета Небраски
https://doi.org/10.32415/jscientia_2021_7_6_28-70
Ключевые слова:
COVID-19, коронавирусы, SARS-CoV-2, онкологические заболевания, воспаление, сопутствующая патологияАннотация
Коронавирусная инфекция 2019 года (COVID-19) — это вирусное заболевание, вызываемое новым коронавирусом тяжелого острого респираторного синдрома, SARS-CoV-2, который поражает легкие инфицированных лиц. COVID-19 распространяется от человека к человеку посредством респираторных капель, выделяющихся при кашле или чихании инфицированного. Эпидемия COVID-19 началась в городе Ухань (Китай) в конце 2019 года. По состоянию на 29 сентября 2020 года более 235 стран, районов или территорий по всему миру сообщили в общей сложности о 33 441 919 подтвержденных случаях заболевания и о 1 003 497 подтвержденных смертях от COVID-19. Риску заражения подвержены люди любого возраста, но в большинстве случаев тяжелое течение заболевания наблюдается у людей старшей возрастной группы и при наличии сопутствующей патологии, которая снижает иммунитет, например, онкологических заболеваний. Данные многочисленных исследований позволяют предполагать, что пациенты со злокачественными новообразованиями могут быть подвержены более высокому риску тяжелого течения COVID-19 и летального исхода. Поэтому оказание онкологической помощи в условиях пандемии является сложной задачей и требует совместного междисциплинарного подхода для оптимального лечения онкологических больных в условиях стационара. В этом расширенном обзоре мы обсуждаем влияние пандемии COVID-19 на онкологических больных и оказание им медицинской помощи. Помимо этого, обзор содержит общие сведения о пандемии, вызванной SARS-CoV-2, характеристику генома вируса, описание патофизиологии COVID-19 и связанных с ней сигнальных путей, играющих важную роль при онкопатологии, а также информацию о вариантах использования противоопухолевых средств для лечения COVID-19.
Оригинал статьи: Pathania AS, Prathipati P, Abdul BAA, et al. COVID-19 and Cancer Comorbidity: Therapeutic Opportunities and Challenges. Theranostics. 2021;11(2):731-753. DOI: 10.7150/thno.51471.
Статья переведена на русский язык и опубликована согласно условиям лицензии Creative Commons Attribution 4.0.
Библиографические ссылки
Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733. DOI: 10.1056/NEJMoa2001017
Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020;382(10):929-936. DOI: 10.1056/NEJMoa2001191
Cohen J, Normile D. New SARS-like virus in China triggers alarm. Science. 2020;367(6475):234-235. DOI: 10.1126/science.367.6475.234
Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433. DOI: 10.1016/j.jaut.2020.102433
Singu S, Acharya A, Challagundla K, Byrareddy SN. Impact of Social Determinants of Health on the Emerging COVID-19 Pandemic in the United States. Front Public Health. 2020;8:406. DOI: 10.3389/fpubh.2020.00406
Li P, Kaslan M, Lee SH, et al. Progress in Exosome Isolation Techniques. Theranostics. 2017;7(3):789-804. DOI: 10.7150/thno.18133
Liu J, Liao X, Qian S, et al. Community Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, Shenzhen, China, 2020. Emerg Infect Dis. 2020;26(6):1320-1323. DOI: 10.3201/eid2606.200239
Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514-523. DOI: 10.1016/S0140-6736(20)30154-9
Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020;382(13):1199-1207. DOI: 10.1056/NEJMoa2001316
Santarpia JL, Rivera DN, Herrera VL, et al. Aerosol and surface contamination of SARS-CoV-2 observed in quarantine and isolation care. Sci Rep. 2020;10(1):12732. DOI: 10.1038/s41598-020-69286-3
Brodeur GM, Seeger RC, Schwab M, et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984;224(4653):1121-1124. DOI: 10.1126/science.6719137
Cholankeril G, Podboy A, Aivaliotis VI, et al. High Prevalence of Concurrent Gastrointestinal Manifestations in Patients With Severe Acute Respiratory Syndrome Coronavirus 2: Early Experience From California. Gastroenterology. 2020;159(2):775-777. DOI: 10.1053/j.gastro.2020.04.008
Liu F, Zhang Q, Huang C, et al. CT quantification of pneumonia lesions in early days predicts progression to severe illness in a cohort of COVID-19 patients. Theranostics. 2020;10(12):5613-5622. DOI: 10.7150/thno.45985
Zhao W, Zhong Z, Xie X, et al. CT Scans of Patients with 2019 Novel Coronavirus (COVID-19) Pneumonia. Theranostics. 2020;10(10):4606-4613. DOI: 10.7150/thno.45016
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. DOI: 10.1016/S0140-6736(20)30183-5
Götzinger F, Santiago-García B, Noguera-Julián A, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health. 2020;4(9):653-661. DOI: 10.1016/S2352-4642(20)30177-2
Cao J, Zheng Y, Luo Z, et al. Myocardial injury and COVID-19: Serum hs-cTnI level in risk stratification and the prediction of 30-day fatality in COVID-19 patients with no prior cardiovascular disease. Theranostics. 2020;10(21):9663-9673. DOI: 10.7150/thno.47980
Tersalvi G, Veronese G, Winterton D. Emerging evidence of myocardial injury in COVID-19: A path through the smoke. Theranostics. 2020;10(21):9888-9889. DOI: 10.7150/thno.50788
Dai M, Liu D, Liu M, et al. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov. 2020;10(6):783-791. DOI: 10.1158/2159-8290.CD-20-0422
Li Y, Han X, Alwalid O, et al. Baseline characteristics and risk factors for short-term outcomes in 132 COVID-19 patients with diabetes in Wuhan China: A retrospective study. Diabetes Res Clin Pract. 2020;166:108299. DOI: 10.1016/j.diabres.2020.108299
Nishiga M, Wang DW, Han Y, et al. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol. 2020;17(9):543-558. DOI: 10.1038/s41569-020-0413-9
What's New in the Guidelines. URL: https://www.covid19treatmentguidelines.nih.gov/whats-new.
Chan JF, Kok KH, Zhu Z, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221-236. DOI: 10.1080/22221751.2020.1719902
Wang H, Li X, Li T, et al. The genetic sequence, origin, and diagnosis of SARS-CoV-2. Eur J Clin Microbiol Infect Dis. 2020;39(9):1629-1635. DOI: 10.1007/s10096-020-03899-4
Walls AC, Park YJ, Tortorici MA, et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181(2):281-292.e6. DOI: 10.1016/j.cell.2020.02.058
Wan Y, Shang J, Graham R, et al. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J Virol. 2020;94(7):e00127-20. DOI: 10.1128/JVI.00127-20
Premkumar L, Segovia-Chumbez B, Jadi R, et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol. 2020;5(48):eabc8413. DOI: 10.1126/sciimmunol.abc8413
Hoffmann M, Kleine-Weber H, Pöhlmann S. A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells. Mol Cell. 2020;78(4):779-784.e5. DOI: 10.1016/j.molcel.2020.04.022
Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260-1263. DOI: 10.1126/science.abb2507
Andersen KG, Rambaut A, Lipkin WI, et al. The proximal origin of SARS-CoV-2. Nat Med. 2020;26(4):450-452. DOI: 10.1038/s41591-020-0820-9
Burkard C, Verheije MH, Wicht O, et al. Coronavirus cell entry occurs through the endo-/lysosomal pathway in a proteolysis-dependent manner. PLoS Pathog. 2014;10(11):e1004502. DOI: 10.1371/journal.ppat.1004502
Milewska A, Nowak P, Owczarek K, et al. Entry of Human Coronavirus NL63 into the Cell. J Virol. 2018;92(3):e01933-17. DOI: 10.1128/JVI.01933-17
Jaimes JA, Millet JK, Whittaker GR. Proteolytic Cleavage of the SARS-CoV-2 Spike Protein and the Role of the Novel S1/S2 Site. iScience. 2020;23(6):101212. DOI: 10.1016/j.isci.2020.101212
Bagdonaite I, Wandall HH. Global aspects of viral glycosylation. Glycobiology. 2018;28(7):443-467. DOI: 10.1093/glycob/cwy021
Cook JD, Lee JE. The secret life of viral entry glycoproteins: moonlighting in immune evasion. PLoS Pathog. 2013;9(5):e1003258. DOI: 10.1371/journal.ppat.1003258
Tse LV, Hamilton AM, Friling T, Whittaker GR. A novel activation mechanism of avian influenza virus H9N2 by furin. J Virol. 2014;88(3):1673-1683. DOI: 10.1128/JVI.02648-13
van Dorp L, Acman M, Richard D, et al. Emergence of genomic diversity and recurrent mutations in SARS-CoV-2. Infect Genet Evol. 2020;83:104351. DOI: 10.1016/j.meegid.2020.104351
Graham RL, Sparks JS, Eckerle LD, et al. SARS coronavirus replicase proteins in pathogenesis. Virus Res. 2008;133(1):88-100. DOI: 10.1016/j.virusres.2007.02.017
Forni D, Cagliani R, Mozzi A, et al. Extensive Positive Selection Drives the Evolution of Nonstructural Proteins in Lineage C Betacoronaviruses. J Virol. 2016;90(7):3627-3639. DOI: 10.1128/JVI.02988-15
Angeletti S, Benvenuto D, Bianchi M, et al. COVID-2019: The role of the nsp2 and nsp3 in its pathogenesis. J Med Virol. 2020;92(6):584-588. DOI: 10.1002/jmv.25719
Pachetti M, Marini B, Benedetti F, et al. Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant. J Transl Med. 2020;18(1):179. DOI: 10.1186/s12967-020-02344-6
Wang C, Liu Z, Chen Z, et al. The establishment of reference sequence for SARS-CoV-2 and variation analysis. J Med Virol. 2020;92(6):667-674. DOI: 10.1002/jmv.25762
Kang DH, Weaver MT, Park NJ, et al. Significant impairment in immune recovery after cancer treatment. Nurs Res. 2009;58(2):105-114. DOI: 10.1097/NNR.0b013e31818fcecd
Wu MY, Li CJ, Yiang GT, et al. Molecular Regulation of Bone Metastasis Pathogenesis. Cell Physiol Biochem. 2018;46(4):1423-1438. DOI: 10.1159/000489184
Rogado J, Pangua C, Serrano-Montero G, et al. Covid-19 and lung cancer: A greater fatality rate? Lung Cancer. 2020;146:19-22. DOI: 10.1016/j.lungcan.2020.05.034
Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020;31(7):894-901. DOI: 10.1016/j.annonc.2020.03.296
Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907-1918. DOI: 10.1016/S0140-6736(20)31187-9
Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335-337. DOI: 10.1016/S1470-2045(20)30096-6
Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA. 2020;323(18):1775-1776. DOI: 10.1001/jama.2020.4683
Trapani D, Marra A, Curigliano G. The experience on coronavirus disease 2019 and cancer from an oncology hub institution in Milan, Lombardy Region. Eur J Cancer. 2020;132:199-206. DOI: 10.1016/j.ejca.2020.04.017
Park JR, Bagatell R, London WB, et al. Children's Oncology Group's 2013 blueprint for research: neuroblastoma. Pediatr Blood Cancer. 2013;60(6):985-993. DOI: 10.1002/pbc.24433
Mehta V, Goel S, Kabarriti R, et al. Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. Cancer Discov. 2020;10(7):935-941. DOI: 10.1158/2159-8290.CD-20-0516
Lara Álvarez MÁ, Rogado Revuelta J, Obispo Portero B, et al. COVID-19 mortality in cancer patients in a Madrid hospital during the first 3 weeks of the epidemic. Med Clin (Engl Ed). 2020;155(5):202-204. DOI: 10.1016/j.medcle.2020.05.012
Rugge M, Zorzi M, Guzzinati S. SARS-CoV-2 infection in the Italian Veneto region: adverse outcomes in patients with cancer. Nat Cancer. 2020;1(8):784-788. DOI: 10.1038/s43018-020-0104-9
Luo J, Rizvi H, Preeshagul IR, et al. COVID-19 in patients with lung cancer. Ann Oncol. 2020;31(10):1386-1396. DOI: 10.1016/j.annonc.2020.06.007
Garassino MC, Whisenant JG, Huang LC, et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 2020;21(7):914-922. DOI: 10.1016/S1470-2045(20)30314-4
Passamonti F, Cattaneo C, Arcaini L, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7(10):e737-e745. DOI: 10.1016/S2352-3026(20)30251-9
Sanchez-Pina JM, Rodríguez Rodriguez M, Castro Quismondo N, et al. Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies. Eur J Haematol. 2020;105(5):597-607. DOI: 10.1111/ejh.13493
Vuagnat P, Frelaut M, Ramtohul T, et al. COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area. Breast Cancer Res. 2020;22(1):55. DOI: 10.1186/s13058-020-01293-8
Aries JA, Davies JK, Auer RL, et al. Clinical outcome of coronavirus disease 2019 in haemato-oncology patients. Br J Haematol. 2020;190(2):e64-e67. DOI: 10.1111/bjh.16852
Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581(7807):215-220. DOI: 10.1038/s41586-020-2180-5
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-280.e8. DOI: 10.1016/j.cell.2020.02.052
Burrell LM, Johnston CI, Tikellis C, Cooper ME. ACE2, a new regulator of the renin-angiotensin system. Trends Endocrinol Metab. 2004;15(4):166-169. DOI: 10.1016/j.tem.2004.03.001
Hamming I, Timens W, Bulthuis ML, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631-637. DOI: 10.1002/path.1570
Devaux CA, Rolain JM, Raoult D. ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. J Microbiol Immunol Infect. 2020;53(3):425-435. DOI: 10.1016/j.jmii.2020.04.015
Chen J, Jiang Q, Xia X, et al. Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation. Aging Cell. 2020;19(7):e13168. DOI: 10.1111/acel.13168
Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-273. DOI: 10.1038/s41586-020-2012-7
Shang J, Wan Y, Luo C, et al. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci U S A. 2020;117(21):11727-11734. DOI: 10.1073/pnas.2003138117
Deshotels MR, Xia H, Sriramula S, et al. Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation through an angiotensin II type I receptor-dependent mechanism. Hypertension. 2014;64(6):1368-1375. DOI: 10.1161/HYPERTENSIONAHA.114.03743
Benigni A, Cassis P, Remuzzi G. Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med. 2010;2(7):247-257. DOI: 10.1002/emmm.201000080
Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med. 2020;383(4):334-346. DOI: 10.1056/NEJMoa2021680
Zong H, Yin B, Zhou H, et al. Loss of angiotensin-converting enzyme 2 promotes growth of gallbladder cancer. Tumour Biol. 2015;36(7):5171-5177. DOI: 10.1007/s13277-015-3171-2
Yu C, Tang W, Wang Y, et al. Downregulation of ACE2/Ang-(1-7)/Mas axis promotes breast cancer metastasis by enhancing store-operated calcium entry. Cancer Lett. 2016;376(2):268-277. DOI: 10.1016/j.canlet.2016.04.006
Zhou L, Zhang R, Yao W, et al. Decreased expression of angiotensin-converting enzyme 2 in pancreatic ductal adenocarcinoma is associated with tumor progression. Tohoku J Exp Med. 2009;217(2):123-131. DOI: 10.1620/tjem.217.123
Xu J, Fan J, Wu F, et al. The ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Pleiotropic Roles in Cancer. Front Physiol. 2017;8:276. DOI: 10.3389/fphys.2017.00276
Qian YR, Guo Y, Wan HY, et al. Angiotensin-converting enzyme 2 attenuates the metastasis of non-small cell lung cancer through inhibition of epithelial-mesenchymal transition. Oncol Rep. 2013;29(6):2408-2414. DOI: 10.3892/or.2013.2370
Stewart CA, Gay CM, Ramkumar K, et al. SARS-CoV-2 infection induces EMT-like molecular changes, including ZEB1-mediated repression of the viral receptor ACE2, in lung cancer models. bioRxiv. 2020;Version 1: Preprint. 2020 May 29
Yang J, Li H, Hu S, Zhou Y. ACE2 correlated with immune infiltration serves as a prognostic biomarker in endometrial carcinoma and renal papillary cell carcinoma: implication for COVID-19. Aging (Albany NY). 2020;12(8):6518-6535. DOI: 10.18632/aging.103100
Ehrlich M. DNA hypomethylation in cancer cells. Epigenomics. 2009;1(2):239-259. DOI: 10.2217/epi.09.33
Lucas JM, Heinlein C, Kim T, et al. The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Discov. 2014;4(11):1310-1325. DOI: 10.1158/2159-8290.CD-13-1010
Wang Q, Li W, Liu XS, et al. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell. 2007;27(3):380-392. DOI: 10.1016/j.molcel.2007.05.041
Shaw GL, Whitaker H, Corcoran M, et al. The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer. Eur Urol. 2016;70(2):214-218. DOI: 10.1016/j.eururo.2015.10.042
Montopoli M, Zumerle S, Vettor R, et al. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532). Ann Oncol. 2020;31(8):1040-1045. DOI: 10.1016/j.annonc.2020.04.479
Burgueño JF, Reich A, Hazime H, et al. Expression of SARS-CoV-2 Entry Molecules ACE2 and TMPRSS2 in the Gut of Patients With IBD. Inflamm Bowel Dis. 2020;26(6):797-808. DOI: 10.1093/ibd/izaa085
Zang R, Gomez Castro MF, McCune BT, et al. TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. Sci Immunol. 2020;5(47):eabc3582. DOI: 10.1126/sciimmunol.abc3582
Wu ZS, Zhang ZQ, Wu S. Focus on the Crosstalk between COVID-19 and Urogenital Systems. J Urol. 2020;204(1):7-8. DOI: 10.1097/JU.0000000000001068
Vaarala MH, Porvari K, Kyllönen A, et al. The TMPRSS2 gene encoding transmembrane serine protease is overexpressed in a majority of prostate cancer patients: detection of mutated TMPRSS2 form in a case of aggressive disease. Int J Cancer. 2001;94(5):705-710. DOI: 10.1002/ijc.1526
Bahmad HF, Abou-Kheir W. Crosstalk between COVID-19 and prostate cancer. Prostate Cancer Prostatic Dis. 2020;23(4):561-563. DOI: 10.1038/s41391-020-0262-y
Spitz R, Hero B, Simon T, Berthold F. Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma. Clin Cancer Res. 2006;12(11 Pt 1):3368-3373. DOI: 10.1158/1078-0432.CCR-05-2495
Xu PP, Tian RH, Luo S, et al. Risk factors for adverse clinical outcomes with COVID-19 in China: a multicenter, retrospective, observational study. Theranostics. 2020;10(14):6372-6383. DOI: 10.7150/thno.46833
Spitz R, Hero B, Westermann F, et al. Fluorescence in situ hybridization analyses of chromosome band 1p36 in neuroblastoma detect two classes of alterations. Genes Chromosomes Cancer. 2002;34(3):299-305. DOI: 10.1002/gcc.10070
https://www.cdc.gov/coronavirus/2019-ncov/hcp/non-us-settings/overview
Datta PK, Liu F, Fischer T, et al. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy. Theranostics. 2020;10(16):7448-7464. DOI: 10.7150/thno.48076
Sungnak W, Huang N, Bécavin C, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 2020;26(5):681-687. DOI: 10.1038/s41591-020-0868-6
Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools. Virol Sin. 2020;35(3):266-271. DOI: 10.1007/s12250-020-00207-4
Tian S, Hu W, Niu L, et al. Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer. J Thorac Oncol. 2020;15(5):700-704. DOI: 10.1016/j.jtho.2020.02.010
Tian J, Yuan X, Xiao J, et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020;21(7):893-903. DOI: 10.1016/S1470-2045(20)30309-0
Diao B, Wang C, Tan Y, et al. Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19). Front Immunol. 2020;11:827. DOI: 10.3389/fimmu.2020.00827
McDermott DF, Atkins MB. PD-1 as a potential target in cancer therapy. Cancer Med. 2013;2(5):662-673. DOI: 10.1002/cam4.106
Vanni G, Materazzo M, Pellicciaro M, et al. Breast Cancer and COVID-19: The Effect of Fear on Patients' Decision-making Process. In Vivo. 2020;34(3 Suppl):1651-1659. DOI: 10.21873/invivo.11957
Ñamendys-Silva SA. Respiratory support for patients with COVID-19 infection. Lancet Respir Med. 2020;8(4):e18. DOI: 10.1016/S2213-2600(20)30110-7
Ledford H. Coronavirus breakthrough: dexamethasone is first drug shown to save lives. Nature. 2020;582(7813):469. DOI: 10.1038/d41586-020-01824-5
Arshad S, Kilgore P, Chaudhry ZS, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Infect Dis. 2020;97:396-403. DOI: 10.1016/j.ijid.2020.06.099
Rosa SGV, Santos WC. Clinical trials on drug repositioning for COVID-19 treatment. Rev Panam Salud Publica. 2020;44:e40. DOI: 10.26633/RPSP.2020.40
Piechotta V, Chai KL, Valk SJ, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev. 2020;7(7):CD013600. DOI: 10.1002/14651858.CD013600.pub2
Michot JM, Albiges L, Chaput N, et al. Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. Ann Oncol. 2020;31(7):961-964. DOI: 10.1016/j.annonc.2020.03.300
Wan Y, Shang J, Graham R, et al. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J Virol. 2020;94(7):e00127-20. DOI: 10.1128/JVI.00127-20
Fox RI. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum. 1993;23(2 Suppl 1):82-91. DOI: 10.1016/s0049-0172(10)80012-5
Nirk EL, Reggiori F, Mauthe M. Hydroxychloroquine in rheumatic autoimmune disorders and beyond. EMBO Mol Med. 2020;12(8):e12476. DOI: 10.15252/emmm.202012476
Piconi S, Parisotto S, Rizzardini G, et al. Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. Blood. 2011;118(12):3263-3272. DOI: 10.1182/blood-2011-01-329060
Yao TT, Qian JD, Zhu WY, et al. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option. J Med Virol. 2020;92(6):556-563. DOI: 10.1002/jmv.25729
Rivera DR, Peters S, Panagiotou OA, et al. Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. Cancer Discov. 2020;10(10):1514-1527. DOI: 10.1158/2159-8290.CD-20-0941
Geleris J, Sun Y, Platt J, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020;382(25):2411-2418. DOI: 10.1056/NEJMoa2012410
Rosenberg ES, Dufort EM, Udo T, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. JAMA. 2020;323(24):2493-2502. DOI: 10.1001/jama.2020.8630
RECOVERY Collaborative Group, Horby P, Mafham M, et al. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020;383(21):2030-2040. DOI: 10.1056/NEJMoa2022926
https://www.nih.gov/news-events/news-releases/nih-halts-clinical-trial-hydroxychloroquine
Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020;20(6):355-362. DOI: 10.1038/s41577-020-0331-4
Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020;117(20):10970-10975. DOI: 10.1073/pnas.2005615117
Liu J, Wan M, Lyon CJ, Hu TY. Nanomedicine therapies modulating Macrophage Dysfunction: a potential strategy to attenuate Cytokine Storms in severe infections. Theranostics. 2020;10(21):9591-9600. DOI: 10.7150/thno.47982
Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020;2(8):e474-e484. DOI: 10.1016/S2665-9913(20)30173-9
Campochiaro C, Della-Torre E, Cavalli G, et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med. 2020;76:43-49. DOI: 10.1016/j.ejim.2020.05.021
Magee DJ, Jhanji S, Poulogiannis G, et al. Nonsteroidal anti-inflammatory drugs and pain in cancer patients: a systematic review and reappraisal of the evidence. Br J Anaesth. 2019;123(2):e412-e423. DOI: 10.1016/j.bja.2019.02.028
Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-867. DOI: 10.1038/nature01322
Renner A, Marth K, Patocka K, Pohl W. COVID-19 in a severe eosinophilic asthmatic receiving benralizumab - a case study. J Asthma. 2021;58(9):1270-1272. DOI: 10.1080/02770903.2020.1781165
García-Moguel I, Díaz Campos R, Alonso Charterina S, et al. COVID-19, severe asthma, and biologics. Ann Allergy Asthma Immunol. 2020;125(3):357-359.e1. DOI: 10.1016/j.anai.2020.06.012
Kaplan SS, Hicks CB. Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection. Expert Opin Pharmacother. 2005;6(9):1573-1585. DOI: 10.1517/14656566.6.9.1573
Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020;382(19):1787-1799. DOI: 10.1056/NEJMoa2001282
Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;395(10238):1695-1704. DOI: 10.1016/S0140-6736(20)31042-4
Group RC, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med. 2020: Published on July 17, 2020.
Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12(1):8. DOI: 10.1038/s41368-020-0074-x
Cook AM, McDonnell AM, Lake RA, Nowak AK. Dexamethasone co-medication in cancer patients undergoing chemotherapy causes substantial immunomodulatory effects with implications for chemo-immunotherapy strategies. Oncoimmunology. 2015;5(3):e1066062. DOI: 10.1080/2162402X.2015.1066062
Rubinstein SM, Steinharter JA, Warner J, et al. The COVID-19 and Cancer Consortium: A Collaborative Effort to Understand the Effects of COVID-19 on Patients with Cancer. Cancer Cell. 2020;37(6):738-741. DOI: 10.1016/j.ccell.2020.04.018
Ceschi A, Noseda R, Palin K, Verhamme K. Immune Checkpoint Inhibitor-Related Cytokine Release Syndrome: Analysis of WHO Global Pharmacovigilance Database. Front Pharmacol. 2020;11:557. DOI: 10.3389/fphar.2020.00557
Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565-574. DOI: 10.1016/S0140-6736(20)30251-8
Lau SK, Woo PC, Yip CC, et al. Coronavirus HKU1 and other coronavirus infections in Hong Kong. J Clin Microbiol. 2006;44(6):2063-2071. DOI: 10.1128/JCM.02614-05
Kumar D, Dey T. Treatment delays in oncology patients during COVID-19 pandemic: A perspective. J Glob Health. 2020;10(1):010367. DOI: 10.7189/jogh.10.010367
Matsuo T, Kobayashi D, Taki F, et al. Prevalence of Health Care Worker Burnout During the Coronavirus Disease 2019 (COVID-19) Pandemic in Japan. JAMA Netw Open. 2020;3(8):e2017271. DOI: 10.1001/jamanetworkopen.2020.17271
Rajkumar RP. COVID-19 and mental health: A review of the existing literature. Asian J Psychiatr. 2020;52:102066. DOI: 10.1016/j.ajp.2020.102066
Ochoa Arnedo C, Sánchez N, Sumalla EC, Casellas-Grau A. Stress and Growth in Cancer: Mechanisms and Psychotherapeutic Interventions to Facilitate a Constructive Balance. Front Psychol. 2019;10:177. DOI: 10.3389/fpsyg.2019.00177
Tsamakis K, Triantafyllis AS, Tsiptsios D, et al. COVID-19 related stress exacerbates common physical and mental pathologies and affects treatment (Review). Exp Ther Med. 2020;20(1):159-162. DOI: 10.3892/etm.2020.8671
https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic
Richards M, Anderson M, Carter P, et al. The impact of the COVID-19 pandemic on cancer care. Nat Cancer. 2020;1(6):565-567. DOI: 10.1038/s43018-020-0074-y
Dietz JR, Moran MS, Isakoff SJ, et al. Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium. Breast Cancer Res Treat. 2020;181(3):487-497. DOI: 10.1007/s10549-020-05644-z
Shinder BM, Patel HV, Sterling J, et al. Urologic oncology surgery during COVID-19: a rapid review of current triage guidance documents. Urol Oncol. 2020;38(7):609-614. DOI: 10.1016/j.urolonc.2020.05.017
Verma R, Foster RE, Horgan K, et al. Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer. Breast Cancer Res. 2016;18(1):10. DOI: 10.1186/s13058-015-0669-x
Payne K. Ethical issues related to pandemic flu planning and response. AACN Adv Crit Care. 2007;18(4):356-360. DOI: 10.1097/01.AACN.0000298627.07535.76
Adams DP. Wartime bureaucracy and penicillin allocation: the Committee on Chemotherapeutic and Other Agents, 1942-44. J Hist Med Allied Sci. 1989;44(2):196-217. DOI: 10.1093/jhmas/44.2.196
Rosenbaum L. Facing Covid-19 in Italy - Ethics, Logistics, and Therapeutics on the Epidemic's Front Line. N Engl J Med. 2020;382(20):1873-1875. DOI: 10.1056/NEJMp2005492
Xie J, Tong Z, Guan X, et al. Clinical Characteristics of Patients Who Died of Coronavirus Disease 2019 in China. JAMA Netw Open. 2020;3(4):e205619. DOI: 10.1001/jamanetworkopen.2020.5619
Monaghesh E, Hajizadeh A. The role of telehealth during COVID-19 outbreak: a systematic review based on current evidence. BMC Public Health. 2020;20(1):1193. DOI: 10.1186/s12889-020-09301-4
Lesslie M, Parikh JR. Implementing a Multidisciplinary Tumor Board in the Community Practice Setting. Diagnostics (Basel). 2017;7(4):55. DOI: 10.3390/diagnostics7040055
Wein W. Drug development: successes, problems and pitfalls-the industry perspective. ESMO Open. 2016;1(1):e000033. DOI: 10.1136/esmoopen-2016-000033
Yella JK, Yaddanapudi S, Wang Y, Jegga AG. Changing Trends in Computational Drug Repositioning. Pharmaceuticals (Basel). 2018;11(2):57. DOI: 10.3390/ph11020057
Kale VP, Habib H, Chitren R, et al. Old drugs, new uses: Drug repurposing in hematological malignancies. Semin Cancer Biol. 2021;68:242-248. DOI: 10.1016/j.semcancer.2020.03.005
Zhou Y, Hou Y, Shen J, et al. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov. 2020;6:14. DOI: 10.1038/s41421-020-0153-3
Fan HH, Wang LQ, Liu WL, et al. Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model. Chin Med J (Engl). 2020;133(9):1051-1056. DOI: 10.1097/CM9.0000000000000797
Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020;19(3):149-150. DOI: 10.1038/d41573-020-00016-0
Liu X, Liu C, Liu G, et al. COVID-19: Progress in diagnostics, therapy and vaccination. Theranostics. 2020;10(17):7821-7835. DOI: 10.7150/thno.47987
Du Y, Tu L, Zhu P, et al. Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan. A Retrospective Observational Study. Am J Respir Crit Care Med. 2020;201(11):1372-1379. DOI: 10.1164/rccm.202003-0543OC
Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, et al. SARS-CoV-2 infection: The role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020;54:62-75. DOI: 10.1016/j.cytogfr.2020.06.001
Ragab D, Salah Eldin H, Taeimah M, et al. The COVID-19 Cytokine Storm; What We Know So Far. Front Immunol. 2020;11:1446. DOI: 10.3389/fimmu.2020.01446
Mascarenhas J, Hoffman R. Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clin Cancer Res. 2012;18(11):3008-3014. DOI: 10.1158/1078-0432.CCR-11-3145
Lussana F, Rambaldi A. Inflammation and myeloproliferative neoplasms. J Autoimmun. 2017;85:58-63. DOI: 10.1016/j.jaut.2017.06.010
La Rosée F, Bremer HC, Gehrke I, et al. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. Leukemia. 2020;34(7):1805-1815. DOI: 10.1038/s41375-020-0891-0
Roschewski M, Lionakis MS, Sharman JP, et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci Immunol. 2020;5(48):eabd0110. DOI: 10.1126/sciimmunol.abd0110
https://www.cancer.gov/news-events/cancer-currents-blog/2017/acalabrutinib-fda-mantle-cell-lymphoma
Lee KG, Xu S, Kang ZH, et al. Bruton's tyrosine kinase phosphorylates Toll-like receptor 3 to initiate antiviral response. Proc Natl Acad Sci U S A. 2012;109(15):5791-5796. DOI: 10.1073/pnas.1119238109
Weber ANR, Bittner Z, Liu X, et al. Bruton's Tyrosine Kinase: An Emerging Key Player in Innate Immunity. Front Immunol. 2017;8:1454. DOI: 10.3389/fimmu.2017.01454
Zhou Q, Chen V, Shannon CP, et al. Interferon-α2b Treatment for COVID-19. Front Immunol. 2020;11:1061. DOI: 10.3389/fimmu.2020.01061
Yeager CL, Ashmun RA, Williams RK, et al. Human aminopeptidase N is a receptor for human coronavirus 229E. Nature. 1992;357(6377):420-422. DOI: 10.1038/357420a0
Asmana Ningrum R. Human interferon alpha-2b: a therapeutic protein for cancer treatment. Scientifica (Cairo). 2014;2014:970315. DOI: 10.1155/2014/970315
Xu P, Huang J, Fan Z, et al. Arbidol/IFN-α2b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study. Microbes Infect. 2020;22(4-5):200-205. DOI: 10.1016/j.micinf.2020.05.012
Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020;382(24):2327-2336. DOI: 10.1056/NEJMoa2007016
Morton JJ, Bird G, Refaeli Y, Jimeno A. Humanized Mouse Xenograft Models: Narrowing the Tumor-Microenvironment Gap. Cancer Res. 2016;76(21):6153-6158. DOI: 10.1158/0008-5472.CAN-16-1260
Jiang Y, Chen D, Cai D, et al. Effectiveness of remdesivir for the treatment of hospitalized COVID-19 persons: A network meta-analysis. J Med Virol. 2021;93(2):1171-1174. DOI: 10.1002/jmv.26443
Williamson BN, Feldmann F, Schwarz B, et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature. 2020;585(7824):273-276. DOI: 10.1038/s41586-020-2423-5
Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020;383(19):1813-1826. DOI: 10.1056/NEJMoa2007764
Szabo G, Momen-Heravi F. Extracellular vesicles in liver disease and potential as biomarkers and therapeutic targets. Nat Rev Gastroenterol Hepatol. 2017;14(8):455-466. DOI: 10.1038/nrgastro.2017.71
Hashemian SM, Farhadi T, Velayati AA. A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19. Drug Des Devel Ther. 2020;14:3215-3222. DOI: 10.2147/DDDT.S261154
Neogi U, Hill KJ, Ambikan AT, et al. Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs. Pathogens. 2020;9(5):320. DOI: 10.3390/pathogens9050320
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
Wu A, Peng Y, Huang B, et al. Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. Cell Host Microbe. 2020;27(3):325-328. DOI: 10.1016/j.chom.2020.02.001
Zhou H, Chen X, Hu T, et al. A Novel Bat Coronavirus Closely Related to SARS-CoV-2 Contains Natural Insertions at the S1/S2 Cleavage Site of the Spike Protein. Curr Biol. 2020;30(11):2196-2203.e3. DOI: 10.1016/j.cub.2020.05.023
Miyashita H, Mikami T, Chopra N, et al. Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City. Ann Oncol. 2020;31(8):1088-1089. DOI: 10.1016/j.annonc.2020.04.006
Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985. DOI: 10.1136/bmj.m1985
Meng Y, Lu W, Guo E, et al. Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: a propensity score-matched analysis. J Hematol Oncol. 2020;13(1):75. DOI: 10.1186/s13045-020-00907-0
Rogado J, Obispo B, Pangua C, et al. Covid-19 transmission, outcome and associated risk factors in cancer patients at the first month of the pandemic in a Spanish hospital in Madrid. Clin Transl Oncol. 2020;22(12):2364-2368. DOI: 10.1007/s12094-020-02381-z
Gupta S, Hayek SS, Wang W, et al. Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US. JAMA Intern Med. 2020;180(11):1436-1447. DOI: 10.1001/jamainternmed.2020.3596
Yang K, Sheng Y, Huang C, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020;21(7):904-913. DOI: 10.1016/S1470-2045(20)30310-7
Lee LYW, Cazier JB, Starkey T, et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol. 2020;21(10):1309-1316. DOI: 10.1016/S1470-2045(20)30442-3
Lee LY, Cazier JB, Angelis V, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020;395(10241):1919-1926. DOI: 10.1016/S0140-6736(20)31173-9
Robilotti EV, Babady NE, Mead PA, et al. Determinants of COVID-19 disease severity in patients with cancer. Nat Med. 2020;26(8):1218-1223. DOI: 10.1038/s41591-020-0979-0
Mato AR, Roeker LE, Lamanna N, et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020;136(10):1134-1143. DOI: 10.1182/blood.2020006965
Bisogno G, Provenzi M, Zama D, et al. Clinical Characteristics and Outcome of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Italian Pediatric Oncology Patients: A Study From the Infectious Diseases Working Group of the Associazione Italiana di Oncologia e Ematologia Pediatrica. J Pediatric Infect Dis Soc. 2020;9(5):530-534. DOI: 10.1093/jpids/piaa088
Pinato DJ, Lee AJX, Biello F, et al. Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe. Cancers (Basel). 2020;12(7):1841. DOI: 10.3390/cancers12071841
Patel VG, Zhong X, Liaw B, et al. Does androgen deprivation therapy protect against severe complications from COVID-19? Ann Oncol. 2020;31(10):1419-1420. DOI: 10.1016/j.annonc.2020.06.023
Flinn IW, O'Brien S, Kahl B, et al. Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies. Blood. 2018;131(8):877-887. DOI: 10.1182/blood-2017-05-786566
Nelson AM, Gilliland KL, Cong Z, Thiboutot DM. 13-cis Retinoic acid induces apoptosis and cell cycle arrest in human SEB-1 sebocytes. J Invest Dermatol. 2006;126(10):2178-2189. DOI: 10.1038/sj.jid.5700289
Gunda V, Pathania AS, Chava S, et al. Amino Acids Regulate Cisplatin Insensitivity in Neuroblastoma. Cancers (Basel). 2020;12(9):2576. DOI: 10.3390/cancers12092576
Mahapatra S, Challagundla KB. Cancer, Neuroblastoma. StatPearls. Treasure Island (FL). 2020
Chava S, Reynolds CP, Pathania AS, et al. miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma. Mol Oncol. 2020;14(1):180-196. DOI: 10.1002/1878-0261.12588
Challagundla KB, Wise PM, Neviani P, et al. Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy. J Natl Cancer Inst. 2015;107(7):djv135. DOI: 10.1093/jnci/djv135
Mudgapalli N, Shaw BP, Chava S, Challagundla KB. The Transcribed-Ultra Conserved Regions: Novel Non-Coding RNA Players in Neuroblastoma Progression. Noncoding RNA. 2019;5(2):39. DOI: 10.3390/ncrna5020039
Yan P, Frankhouser D, Murphy M, et al. Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. Blood. 2012;120(12):2466-2474. DOI: 10.1182/blood-2012-05-429175
Abraham SM, Lawrence T, Kleiman A, et al. Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. J Exp Med. 2006;203(8):1883-1889. DOI: 10.1084/jem.20060336
Montecucco A, Zanetta F, Biamonti G. Molecular mechanisms of etoposide. EXCLI J. 2015;14:95-108. DOI: 10.17179/excli2015-561
Iqbal N, Iqbal N. Imatinib: a breakthrough of targeted therapy in cancer. Chemother Res Pract. 2014;2014:357027. DOI: 10.1155/2014/357027
Jiang T, Zhou C, Ren S. Role of IL-2 in cancer immunotherapy. Oncoimmunology. 2016;5(6):e1163462. DOI: 10.1080/2162402X.2016.1163462
Fink EC, Ebert BL. The novel mechanism of lenalidomide activity. Blood. 2015;126(21):2366-2369. DOI: 10.1182/blood-2015-07-567958
Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009;2:36. DOI: 10.1186/1756-8722-2-36
Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest. 2001;107(2):135-142. DOI: 10.1172/JCI11914
Fritsch M, Jordan VC. Long-term Tamoxifen Therapy for the Treatment of Breast Cancer. Cancer Control. 1994;1(4):356-366.
Tam CS. Zanubrutinib: a novel BTK inhibitor in chronic lymphocytic leukemia and non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 2019;17(1):32-34.
Tian H, Cronstein BN. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007;65(3):168-173.
Dellis AE, Papatsoris AG. Perspectives on the current and emerging chemical androgen receptor antagonists for the treatment of prostate cancer. Expert Opin Pharmacother. 2019;20(2):163-172. DOI: 10.1080/14656566.2018.1548611
Miller J, Tarter TH. Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate. Clin Interv Aging. 2009;4:251-258. DOI: 10.2147/cia.s4102
Saha A, Sharma AR, Bhattacharya M, et al. Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19: Need to Know More. Arch Med Res. 2020;51(6):585-586. DOI: 10.1016/j.arcmed.2020.05.001
Опубликован
Как цитировать
Лицензия
Copyright (c) 2021 А. С. Патания, Ф. Пратипати, Б. А. А. Абдул, Ш. Чава, С. С. Катта, С. К. Гупта, П. Р. Гангула, М. К. Пандей, Д. Л. Дерден, С. Байраредди, К. Б. Чаллагундла
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.
